Hybribio Biotech secures two new invention patents, enhancing diagnostics

Guangdong Hybribio Biotech Co., Ltd. and its subsidiaries announced the authorization of two invention patents in August 2025. The first patent, "A Primer and Design Method for Detecting Drug-Resistant Genes of Genital Tract Pathogens," enables rapid, multi-target detection of drug-resistant genes and mutation sites. This technology is applicable across various detection platforms, including pathogen sequencing, real-time PCR, and digital PCR.

The second patent, "A Primer Combination and Its Application in Preparing Products for Detecting SNP Loci Related to Antipsychotic Drug Use," focuses on enabling sensitive and specific detection of 18 SNP loci linked to antipsychotic drug response. This innovation facilitates personalized medication guidance for antipsychotic drugs, aiming to prevent ineffective treatment and severe side effects for patients with mental illnesses like schizophrenia.

These patents align with Hybribio Biotech's "Nucleic Acid 99" strategy and its goal of becoming a leader in nucleic acid molecular diagnostics. The intellectual property advancements are expected to enrich the company's product structure, meet diverse market demands, and enhance its core competitiveness, contributing to its strategic development without significantly impacting current operations.